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Recently, we demonstrated that the central ghrelin signalling system, involving the ghrelin receptor (GHS-R1A), is
important for alcohol reinforcement. Ghrelin targets a key mesolimbic circuit involved in natural as well as drug-
induced reinforcement, that includes a dopamine projection from the ventral tegmental area (VTA) to the nucleus
accumbens. The aim of the present study was to determine whether it is possible to suppress ghrelin’s effects on this
mesolimbic dopaminergic pathway can be suppressed, by interrupting afferent inputs to the VTA dopaminergic cells,
as shown previously for cholinergic afferents. Thus, the effects of pharmacological suppression of glutamatergic,
orexin A and opioid neurotransmitter systems on ghrelin-induced activation of the mesolimbic dopamine system were
investigated. We found in the present study that ghrelin-induced locomotor stimulation was attenuated by VTA
administration of the N-methyl-D-aspartic acid receptor antagonist (AP5) but not by VTA administration of an orexin
A receptor antagonist (SB334867) or by peripheral administration of an opioid receptor antagonist (naltrexone).
Intra-VTA administration of AP5 also suppressed the ghrelin-induced dopamine release in the nucleus accumbens.
Finally the effects of peripheral ghrelin on locomotor stimulation and accumbal dopamine release were blocked by
intra-VTA administration of a GHS-R1A antagonist (BIM28163), indicating that GHS-R1A signalling within the VTA
is required for the ghrelin-induced activation of the mesolimbic dopamine system. Given the clinical knowledge that
hyperghrelinemiaisassociatedwithaddictivebehaviours(suchascompulsiveovereatingandalcoholusedisorder)our
ﬁnding highlights a potential therapeutic strategy involving glutamatergic control of ghrelin action at the level of the
mesolimbic dopamine system.
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INTRODUCTION
Ghrelin, a gastric hormone, exerts orexigenic and pro-
obesity effects by interacting with key brain circuits
involved in appetite and energy balance (Tschöp, Smiley
& Heiman 2000; Wren et al. 2000; Cummings et al.
2001; Nakazato et al. 2001). The cloned receptor for
ghrelin (GHS-R1A) is present, however, not only in dis-
crete hypothalamic cell groups regulating energy
balance but also in a number of other central nervous
system (CNS) sites, such as the hippocampus, brainstem
and reinforcement areas (Guan et al. 1997) implying a
role for ghrelin in brain reinforcement. Thus, ghrelin
activates a key mesolimbic circuit involved in natural as
well as drug-induced reinforcement, the cholinergic-
dopaminergic reward link (Jerlhag et al. 2006, 2007,
2008). This link encompasses the well-described dopam-
ine projection from the ventral tegmental area (VTA) to
the nucleus accumbens (N.Acc.) that forms part of the
mesolimbic dopamine system, together with a cholin-
ergic projection from the laterodorsal tegmental area
(LDTg) to the VTA. By activating this reinforcement link,
ghrelin may increase the incentive value of motivated
behaviours such as food and drug seeking (Abizaid et al.
2006; Jerlhag et al. 2006; Jerlhag et al. 2009). Indeed,
alcohol reinforcement was absent in pharmacological
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(Jerlhag et al. 2009).
Peripherally injected ghrelin also stimulates the
mesolimic dopamine system (Jerlhag 2008; Quarta et al.
2009), hypothesizing that peripherally produced ghrelin
reaches deeper brain structures. Moreover, an important
premise for the study is that the afferents regulate ghre-
lin’seffectsonthemesolimbicdopaminesysteminvolving
GHS-R1A in VTA. In the present experiments therefore
wesoughttodeterminewhetherVTAadministrationof a
GHS-R1A antagonist suppresses the locomotor stimula-
tory and accumbal dopamine releasing effects of periph-
eral ghrelin. The activity of VTA dopamine neurons is
modulated by various afferents to the VTA including
glutamate, opioids and orexin (Kalivas, Churchill &
Klitenick1993;Wise2002).Previously,aroleforNMDA,
opioid as well as orexin A receptors in different aspects of
ghrelin-induced activation of the mesolimbic dopamine
systems has been suggested (Toshinai et al. 2003; Naleid
et al. 2005; Abizaid et al. 2006). Inspired by the possibil-
ity to suppress natural and chemical drug reinforcement
by agents that interrupt central ghrelin signalling, we
alsosoughttodeterminewhetherghrelin’sabilitytoacti-
vate the mesolimbic dopamine system, as measured by
locomotor stimulation and accumbal dopamine release,
can be interrupted by pharmacological suppression of
glutamatergic, opioid and orexin A systems.
MATERIALS AND METHODS
Animals
Adultpost-pubertalage-matchedmaleNMRImice(8–12
weeks old and 25-30 g body weight; B&K Universal AB,
Sollentuna, Sweden) were used for studies of locomotor
activity and dopamine release as such studies are well-
documented in this strain (Jerlhag et al. 2006; Jerlhag
et al. 2007; Jerlhag et al. 2008). Upon arrival the mice
were allowed to habituate in groups of eight in standard
cages (Macrolon III: 400 ¥ 250 ¥ 150 mm), for at least
one week before initiation of the experiment. All mice
were maintained at 20°C with 50% humidity and a
12/12 hour light/dark cycle (lights on at 7 am). Tap
water and food (Normal chow; Harlan Teklad, Norfolk,
England) were supplied ad libitum, except during the
experiments. All experiments were conducted during the
day time when the mice are less active. Studies were
approved by the Ethics Committee for Animal Experi-
ments in Gothenburg, Sweden.
Drug administration
Acylated rat ghrelin (Bionuclear; Bromma, Sweden) was
diluted in 0.9% sodium chloride (saline vehicle) and was
administrated intraperitoneally (i.p.) (10 ml/kg body
weight). The selected dose, 0.33 mg/kg, was determined
previously, as it increases locomotor activity and accum-
bal dopamine release as well as induces a conditioned
place preference in mice (Jerlhag 2008). Ghrelin was
administered 10 minutes prior to the initiation of the
experiment (locomotor activity or microdialysis).
The dose of BIM28163 (Ipsen Biomeasure Inc,
Milford, MA, USA), a GHS-R1A antagonist, has also been
determined previously (Halem et al. 2004; Jerlhag et al.
2009). BIM28163 was diluted in Ringer solution (NaCl
140 mM;CaCl21.2 mM;KCl3.0 mMandMgCl21.0 mM)
(Merck KgaA, Darmstadt, Germany) and was adminis-
tered at a dose of 2.5 mg/side (uni- or bilaterally into the
VTA) at 40 minutes prior to i.p. ghrelin/vehicle exposure.
Previous studies have established that this compound is a
GHS-R1A antagonist and fully inhibits ghrelin-induced
GHS-R1A activation (Halem et al. 2004).
The selected dose of AP5 (Sigma-Aldrich, Stockholm,
Sweden), an N-methyl-D-aspartic acid (NMDA) receptor
antagonist, was determined in a dose-response study
where 0.5 mg/side (uni-or bilaterally into the VTA) was
the highest dose not to affect locomotor activity per se
(Fig. 1). AP5 or Ringer vehicle were administered 10
minutes prior to i.p. ghrelin/vehicle administration. AP5
does not affect nicotinic acetylcholine receptors in the
CNS (Davies & Watkins 1982).
Theselecteddoseof SB334867(Tocris,Bristol,United
Kingdom), an orexin A receptor antagonist, was deter-
mined in a dose-response study where 5 mg/side (bilater-
ally into the VTA) was the highest dose not to affect
locomotor activity per se (data not shown). Doses in a
similar range have previously been shown to block the
cue-induced reinstatement of cocaine seeking (Smith,
See & Aston-Jones 2009). SB334867 or vehicle (10%-
DMSO in Ringer vehicle; Merck KgaA) were administered
10 minutes prior to i.p. ghrelin/vehicle exposure.
Naltrexone, an unselective opioid receptor antagonist
with some selectivity to the m receptor, was diluted in
saline vehicle. Naltrexone (1 mg/kg, i.p.) or saline vehicle
wereinjected30minutespriortoi.p.ghrelin/vehicle.The
dose was determined from previous studies in which
doses in a similar range have been shown to block the
reinforcing properties of alcohol in rodents (Herz 1997).
The rationale for administering by the i.p. route is that
direct mesolimbic effects of nalrexone to interrupt
ghrelin-inducedreinforcementareunlikely,basedonpre-
vious studies in which this antagonist had no effect on
ghrelin-induced food intake when administered into dis-
crete mesolimbic sites (Naleid et al. 2005).
Intra-VTA injections were made using a volume of
0.5 ml/side via chronically implanted catheters, over 60
seconds. A 5 ml syringe (Kloehn, microsyringe; Skandi-
naviska Genetec AB, V. Frölunda, Sweden) was used to
facilitate drug administration into the VTA. After each
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seconds to facilitate diffusion. Potentially, the volume
administered during intra-VTA injections could raise
concerns about speciﬁcity due to possible leakage into
neighboring structures. Previously, however, we found
that only ‘on-target’ placements (in the VTA and LDTg
but not in closely adjacent sites) resulted in signiﬁcant
effects of ghrelin or GHS-R1A antagonists on locomotor
stimulation and dopamine release using a larger volume
(1 ml) for mice (Jerlhag et al. 2007, 2009). Supportively,
in the present study neither AP5 nor BIM28163 blocked
ghrelin-induced locomotor stimulation nor accumbal
dopamine release in a few mice in which the canulae
were misplaced in neighbouring structures (data not
shown). All drug challenges were part of a balanced
design with regard to both the treatment order and the
number of subjects per treatment.
Locomotor activity experiments
Peripheral administration of ghrelin has previously been
shown to stimulate locomotor activity in mice (Jerlhag
2008). Locomotor stimulation is, at least in part, medi-
ated by an increase in the extracellular concentration of
accumbal dopamine (Engel et al. 1988). Locomotor
stimulation has been suggested to be an homologous
effect evolving from a common mechanism involving the
mesolimbic dopamine system, implying that locomotor
activity reﬂects reinforcement induced by drugs of abuse
(Imperato&DiChiara1986;Wise&Bozarth1987;Engel
et al. 1988). Thus, accumbal dopamine measurement
experiments were conducted only after ﬁrst establishing
that aforementioned antagonist compounds suppress
ghrelin-induced locomotor stimulation. All mice, except
those treated with naltrexone, were implanted with bilat-
eral guide cannulaes aiming at the VTA. The mice were
anesthetized with isoﬂuran (Isoﬂuran Baxter; Univentor
400 Anaesthesia Unit, Univentor Ldt., Zejtun, Malta),
placed in a stereotaxic frame (David Kopf Instruments;
Tujunga, CA, USA) and kept on a heating pad to prevent
hypothermia. The scull bone was exposed and two holes
for the guide cannulas (stainless steel, length 10 mm,
withano.d./i.d.of 0.6/0.45 mm)andonefortheanchor-
ing screw were drilled. The VTA coordinates were 3.4
posterior to bregma, 0.5 mm lateral to the midline and
1.0 mm below the brain surface (Franklin & Paxinos
1996).Allguidecannulaeweresurgicallyimplantedfour
days prior to the experiment. After surgery the mice were
kept in individual cages (Macrolon III). At the time of the
experiment, a cannula for drug administration was
inserted and extended another 3.8 mm ventrally beyond
the tip of the guide cannula, aiming at the VTA.
Locomotor activity was registered in eight sound
attenuated, ventilated and dim lit locomotor boxes
(420 ¥ 420 ¥ 200 mm, Kungsbacka mät- och reg-
lerteknik AB, Fjärås, Sweden). Five by ﬁve rows of photo-
cell beams, at the ﬂoor level of the box, creating photocell
detectionallowedacomputer-basedsystemtoregisterthe
activityof themice.Locomotoractivitywasdeﬁnedasthe
accumulated number of new photocell beams inter-
rupted during a 60-minute period.
Before initiating the experiments, a dummy cannula
was carefully inserted and retracted into the guide
cannula to remove clotted blood and hamper the spread-
ing depression. Mice were then allowed to habituate to
the locomotor activity box one hour prior to drug chal-
lenge. In separte experiments, the effects of i.p. adminis-
tered ghrelin on locomotor stimulation was investigated
following intra-VTA administration of BIM28163, AP5
or SB334867 to mice. In subsequent experiments, naltr-
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Figure 1 The ghrelin-induced locomotor stimulation and increased accumbal dopamine release are abolished by VTA treatment of the
GHS-R1A antagonist BIM28163.(a) Ghrelin (0.33mg/kg)-induced locomotor stimulation was attenuated byVTA administration of BIM28163
(2.5mg/side) to but not by vehicle injection in mice (F(3,25)=5.45, P=0.005) (n=6–8; **P<0.01; n.s. P>0.05 forVeh-Veh vs. BIM-Ghrelin,
Tukey’s HSD post-hoc test). (b)We ﬁrst demonstrated a signiﬁcant effect of systemic ghrelin to increase dopamine release in comparison to
vehicle treatment (P=0.003) and secondly we showed that pre-treatment with BIM28163 (into the VTA) attenuated the ghrelin-induced
increase in dopamine release compared to vehicle pre-treatment (P=0.001) (treatment F(3,26)=6.39, P=0.002; time F(13,338)=1.77,
P=0.047; treatment-time interaction F(13,338)=4.01, P<0.001).This difference was evident at the time intervals 20–100 minutes (n=7–8;
***P<0.001,Tukey’s HSD post-hoc test).
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motor activity experiment, BIM28163 (2.5 mg/side) or
anequalvolume(0.5 ml/side)of vehiclesolution(Ringer)
was administered locally and bilaterally into the VTA.
Ghrelin(0.33 mg/kg)oranequalvolumeof vehiclesolu-
tion (saline vehicle) was thereafter injected. The same
experimental protocol was used for AP5 (0.5 mg/side),
SB334867(5 mg/side)andnaltrexone(1 mg/kg,i.p.).All
mice received drug treatment only twice (antagonist/
vehicle and ghrelin/vehicle). Neither water nor food was
available to the mice during the locomotor experiments.
The activity registration started ﬁve minutes after the
last injection and was subsequently measured for a
60-minute period. For intra-VTA administration only
mice with guide cannulae placements in the VTA were
included in the statistical analysis.
In vivo microdialysis and dopamine release
measurements
For measurements of extracellular dopamine levels and
overﬂow (that reﬂect dopamine release), mice were
implanted unilaterally with a microdialysis probe posi-
tioned in the N.Acc. shell and a guide cannulae into the
VTA.The probe and the guide cannula/e were positioned
ipsilateral, and the location was randomly alternated to
either the left or right side. The surgery was preformed
two days prior to the experimental day as described above
(see Locomotor activity experiments). The coordinates
for the N.Acc. shell were: 1.5 mm anterior to the
bregma,  0.7 lateral to the midline and 4.7 mm below
the surface of the brain and the coordinates for the VTA
were 3.4 posterior to bregma, 0.5 mm lateral to the
midline and 1.0 mm below the brain surface (Franklin &
Paxinos 1996). At the time of the experiment a cannula
for drug administration was inserted and extended
another 3.8 mm ventrally beyond the tip of the guide
cannula, aiming at the VTA.The exposed tip of the dialy-
sis membrane (20 000 kDa cut off with an o.d./i.d. of
310/220 mm, HOSPAL, Gambro, Lund, Sweden) of the
probe was 1 mm.
In separate experiments, the effects of intra-VTA
administration of AP5, or in separate experiments
BIM28163, on ghrelin-induced accumbal dopamine
release were determined, involving microdialysis in
freely moving mice. On the day of the experiment, a
dummy cannula was carefully inserted and retracted
into the guide cannula. The probe was thereafter con-
nected to a microperfusion pump (U-864 Syringe Pump;
AgnThós AB) and perfused with Ringer solution at a
rate of 1.5 ml/minute. After one hour of habituation to
the microdialysis set-up, perfusion samples were col-
lected every 20 minutes. The baseline dopamine level
was deﬁned as the average of three consecutive samples
before the ﬁrst drug/vehicle challenge. After the baseline
samples, the antagonist (AP5 or BIM28163) was
administered locally into the VTA followed subsequently
by a ghrelin (i.p.) injection. The dopamine levels in the
dialysates were determined by HPLC with electrochemi-
cal detection. A pump (Gyncotec P580A; Kovalent AB;
V. Frölunda, Sweden), an ion exchange column
(2.0 ¥ 100 mm, Prodigy 3 mm SA; Skandinaviska
GeneTec AB; Kungsbacka, Sweden) and a detector
(Antec Decade; Antec Leyden; Zoeterwoude, the Nether-
lands) equipped with a VT-03 ﬂow cell (Antec Leyden)
were used. The mobile phase (pH 5.6), consisting of sul-
fonic acid 10 mM, citric acid 200 mM, sodium citrate
200 mM, 10% EDTA, 30% MeOH, was vacuum ﬁltered
using a 0.2 mm membrane ﬁlter (GH Polypro; PALL
Gelman Laboratory; Lund, Sweden). The mobile phase
was delivered at a ﬂow rate of 0.2 ml/minute passing a
degasser (Kovalent AB), and the analyte was oxidized at
+0.4 V.
Aftercompletionof themicrodialysisexperiments,the
locations of the probe and guide cannulae were veriﬁed.
Neither water nor food were available to the mice during
the microdialysis experiment. Only mice with probe
placement in the N.Acc. and guide cannulae in the VTA
were included in the statistical analysis.
Veriﬁcation of probe and cannula/e placement
After the locomotor activity and microdialysis experi-
ments were completed, the location of the probe and/or
cannula/e were veriﬁed. The mice were decapitated,
probes were perfused with pontamine sky blue 6BX to
facilitate probe localization, and the brains were
mounted on a vibroslice device (752M Vibroslice;
Campden Instruments Ltd, Loughborough, UK). The
brains were cut in 50 mm sections and the location of
the probe and/or cannula/e was determined by gross
observation using light microscopy. The exact position
(some correct and some misplaced) of the probe
and/or guide cannula/e was veriﬁed (Franklin & Paxinos
1996).
Statistical analyses
All locomotor activity data were evaluated by a two-way
ANOVA followed by Tukey’s HSD post-hoc tests compar-
ing treatments. The microdialysis experiments were
evaluated by a two-way ANOVA for repeated measures
followed by Tukey’s HSD post-hoc test for comparisons
between different treatments and speciﬁcally at given
time points. Data are presented as mean  SEM. A prob-
ability value of P < 0.05 was considered as statistically
signiﬁcant.
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Effects of intra-VTA administration of a GHS-R1A
antagonist on ghrelin-induced locomotor stimulation
and accumbal dopamine release in mice
First, the role of GHS-R1A receptors in the VTA for the
reinforcing effects of ghrelin by tests of ghrelin-induced
locomotor stimulation and, in separate studies, by mea-
surement of ghrelin-induced dopamine release were
investigated. The locomotor stimulatory and accumbal
dopamine releasing effects of ghrelin were attenuated
by local administration of the GHS-R1A antagonist
BIM28163 into the VTA (Fig 1a,b), at a dose shown pre-
viously to have no effect on locomotor stimulation and
accumbal dopamine release per se (Jerlhag et al. 2009).
Thus, ghrelin-induced locomotor stimulation (P < 0.01)
was attenuated by VTA administration of BIM28163
(P < 0.01) in mice (F(3,25) = 5.45, P = 0.005: n = 6–8).
In the microdialysis experiments a signiﬁcant effect of
systemic ghrelin to increase dopamine release in com-
parison to vehicle treatment was observed (P = 0.003).
Pre-treatment with BIM28163 attenuated the ghrelin-
induced increase in dopamine release compared with
vehicle pre-treatment in mice (P = 0.001) (treatment
F(3,26) = 6.39, P = 0.002; time F(13,338) = 1.77,
P = 0.047; treatment-time interaction F(13,338) =
4.01, P < 0.001). This difference was evident at
the time intervals 20–100 minutes (P < 0.001:
n = 7–8).
Effects of intra-VTA administration of an orexin A
receptor antagonist or peripheral injection of an opioid
receptor antagonist on ghrelin-induced locomotor
stimulation in mice
The ghrelin-induced locomotor stimulation (P < 0.01)
was not affected by VTA administration of the orexin A
receptor antagonist SB334867 (P > 0.05) in mice
(F(3,24) = 8.44, P = 0.005: n = 6–8) (Fig. 2a). Likewise,
the ghrelin-induced locomotor stimulation (P < 0.01)
was not suppressed by i.p. injection of the opioid receptor
antagonist naltrexone (P > 0.05) in mice (F(3,28) =
6.01, P = 0.003: n = 8) (Fig. 2b).
Effects of intra-VTA administration of a NMDA receptor
antagonist on ghrelin-induced locomotor stimulation
and increased accumbal dopamine release in mice
Intra-VTA administration of the NMDA receptor antago-
nist, AP5, abolished the ghrelin-induced locomotor
stimulation and accumbal dopamine release (Figs 3a,b),
at a dose that had no effect per se (Table 1). Speciﬁcally,
the ghrelin-induced locomotor stimulation (P < 0.01)
was attenuated by VTA administration of AP5
(P < 0.001)inmice(F(3,27) = 8.06,P < 0.001:n = 7-8).
Moreover, systemic ghrelin increased dopamine release
(P < 0.001) and pre-treatment with AP5 attenuated the
Table 1 Effects of intra-VTA administration of different doses of
the NMDA receptor antagonist, AP5, on locomotor activity in
mice per se
Dose AP5 (mg/side)
Locomotor activity
(counts/60 minutes)
0 981  117
0.5 901  43 n.s.
1 449  192**
2 104  25***
The NMDA receptor antagonist, AP5, decreased the locomotor activity at
a dose of 1 mg/side and of 2 mg/side bilaterally into the VTA per se com-
pared to vehicle treatment in mice. However, a dose of 0.5 mg/side bilat-
erally into the VTA did not affect the locomotor activity per se
(F(3,12) = 12.72, P = 0.0005, n = 4 in each group.
**P < 0.01, ***P < 0.001, n.s. P > 0.05, Tukey’s HSD post-hoc test).
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Figure 2 The ghrelin-induced locomotor stimulation is not affected by an orexin A antagonist (SB334867) or an opiod receptor antagonist
(naltrexone).(a) Ghrelin (0.33mg/kg)-induced locomotor stimulation was not affected byVTA administration of SB334867 (5mg/side) in mice
(F(3,24)=8.44, P=0.005) (n=6–8; **P<0.01, ***P<0.001 and n.s. P>0.05,Tukey’s HSD post-hoc test). (b) Ghrelin (0.33mg/kg)-induced
locomotor stimulation was not affected by peripheral administration of naltrexone (1mg/kg) in mice (F(3,28)=6.01, P=0.003) (n=8;
**P<0.01, ***P<0.001 and n.s. P>0.05,Tukey’s HSD post-hoc test).
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pared to vehicle pre-treatment (P < 0.001) (treatment
F(3,36) = 19.98, P < 0.001; time F(12,432) = 3.46,
P < 0.001;treatment-timeinteractionF(12,432) = 5.49,
P < 0.001). This difference was evident at the time inter-
vals 20–180 minutes (P < 0.001: n = 8–11).
Control experiments showed that neither VTA admin-
istration,thevolumeinfusednortheantagonistpersehad
any effect on locomotor activity (Figs 1a, 2a,b and 3a) or
accumbal dopamine release (Figs 1b and 3b).
Probe and cannula/e placements
For all locomotor activity experiments eight mice in each
treatmentgroupwereimplantedwithbilateralguidecan-
nulae,whereas11miceundertooksurgeryforeachtreat-
ment group for the microdialyis experiments. All these
mice were included in the experiments (locomotor activ-
ity or microdialysis studies). After the experiment the
location of the probe and/or guide cannulae was veriﬁed
and only mice with probe placement in the N.Acc. shell
and/or cannula/e in the VTA were included in the statis-
tical analysis (Fig. 4). Neither AP5 nor BIM28163
suppressed ghrelin-induced locomotor stimulation or
accumbal dopamine release in a few mice in which the
canulae were misplaced in neighbouring structures. It
should also be emphasized that in a few mice the probe
was located outside the N.Acc. shell and in these mice no
effect of ghrelin on accumbal dopamine release was
observed (data not shown).
DISCUSSION
The present study demonstrates that the stimulatory
effects of peripheral ghrelin on locomotor stimulation
and accumbal dopamine release involve VTA GHS-R1A
signalling as both effects were suppressed by VTA
administration of a GHS-R1A antagonist (BIM28163).
Moreover, ghrelin’s ability to activate the mesolimbic
dopamine system was suppressed by pharmacological
blockade of glutamatergic receptors but not by blockade
of opioid or orexin A receptors. Thus, the locomotor
stimulating effect of ghrelin was not affected by intra-
VTA administration of the orexin A antagonist
(SB334867) or by peripheral administration of an opioid
receptor antagonist (naltrexone). Finally, ghrelin-
induced locomotor stimulation as well as accumbal
dopaminereleaseweresuppressedbyVTAadministration
of an NMDA receptor antagonist (AP5). Taken together
these data suggest that systemic ghrelin activates the
mesolimbic dopamine system via GHS-R1A in the VTA
and that glutamate rather than orexin or opioid signal-
ling is required for ghrelin to stimulate the mesolimbic
dopamine system.
Given that transport of ghrelin across the blood-brain
barrier into the brain is somewhat limited (Banks et al.
2002), there have been suggestions that ghrelin may
exert its central effects via vagal afferents (Date et al.
2000) or by gaining access at circumventricular organs,
such as the arcuate nucleus and area postrema. Studies
using Fos protein to map ghrelin’s central actions have
shown that whereas peripheral administration of ghrelin
and GHS-R1A agonists activate a rather limited popula-
tion of cells in the arcuate nucleus (Dickson, Leng & Rob-
inson1993;Hewson&Dickson2000)andareapostrema
(Bailey et al. 2000), additional hypothalamic cell groups
were recruited after central administration (Lawrence
et al. 2002). In the present study, it was demonstrated
that the actions of peripheral ghrelin on the midbrain
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Figure 3 The ghrelin-induced locomotor stimulation and increased accumbal dopamine release are abolished by VTA treatment of the
NMDA receptor antagonist AP5. (a) Ghrelin (0.33mg/kg)-induced locomotor stimulation was attenuated by VTA administration of AP5
(0.5mg/side) to but not by vehicle injection in mice (F(3,27)=8.06, P<0.001) (n=7–8; **P<0.01, ***P<0.001; n.s. P>0.05 forVeh-Veh vs.
AP5-Ghrelin,Tukey’s HSD post-hoc test). (b) We ﬁrst demonstrated a signiﬁcant effect of systemic ghrelin to increase dopamine release in
comparison to vehicle treatment (P<0.001) and secondly we showed that pre-treatment with AP5 (into the VTA) attenuated the
ghrelin-induced increase in dopamine release compared to vehicle pre-treatment (P<0.001) (treatment F(3,36)=19.98, P<0.001; time
F(12,432)=3.46, P<0.001; treatment-time interaction F(12,432)=5.49, P<0.001).This difference was evident at the time intervals 20–180
minutes (n=8–11; ***P<0.001,Tukey’s HSD post-hoc test).
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Figure 4 Veriﬁcation of cannula/e and/or probe placement.A coronal mouse brain section showing ten representative probe placements
(illustrated by vertical lines) in the N.Acc. (a) or guide cannula/e placements in the VTA (b) of mice used in the present study (Franklin &
Paxinos 1996).Ten representative placements are illustrated, but all other placements were within the N.Acc. shell or in theVTA. Placements
outside either of these areas were not included in the statistical analysis.The number given in each brain section indicates millimetres anterior
(+) and posterior (-) from bregma.
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accumbal dopamine release, can be blocked by VTA
administration of a GHS-R1A antagonist.Taken together
with previous neuroanatomical and accumbal dopamine
measurement studies showing that the target cells for
ghrelin in the VTA include the dopaminergic cell group
(Abizaid et al. 2006; Jerlhag et al. 2006; Jerlhag 2008;
Kawahara et al. 2009; Quarta et al. 2009), it seems likely
that peripheral ghrelin directly activates the VTA dopam-
ine system via GHS-R1A. The activation of the mesolim-
bic dopamine system by ghrelin may be due to the
reported ability of the GHS-R1A to dimerize with the
dopamine D1 receptor, both receptors expressed on
dopamine neurons in the VTA, and thereby ampliﬁes the
dopamine signalling (Jiang, Betancourt & Smith 2006).
Central ghrelin signalling system, including the GHS-
R1A,appearstoberequiredforreinforcementinducedby
addictive drugs including cocaine (Wellman, Davis &
Nation 2005; Davis, Wellman & Clifford 2007; Tessari
et al. 2007) and alcohol (Jerlhag et al. 2009). The
mesolimbic dopamine system appears to be a likely target
forghrelinalsoinman,asevidencedfromfunctionalMRI
studiesinwhichperipheralghrelinalteredtheresponseof
the ventral striatum to visual food cues (Malik et al.
2008). Indeed, ghrelin may, via VTA GHS-R1A, increase
the incentive value for natural as well as chemical
reinforcements.
Neurotransmitters, including orexin, opioids as well
as glutamate, have previously been shown to modulate
the intake of natural and chemical reinforcers of the
mesolimbic dopamine system as well as to regulate the
activity of these VTA neurons (Hoebel et al. 1989; Engel
et al. 1992; Wise 2002; Thiele et al. 2003). Speciﬁcally,
AP5 and SB334867, in a similar dose range, attenuates
the reinforcing properties of drugs of abuse (Herz 1997;
Taber & Fibiger 1997; Smith et al. 2009). Here, neither
the opioid receptor—nor the orexin A receptor—
antagonist affected ghrelin-induced locomotor stimula-
tion, indicating that these systems do not interfere with
these effects of ghrelin. Consistent with our ﬁndings, the
orexigenic response to ghrelin when administered into
keymesolimbicdopaminestructuressuchastheVTAhas
previouslybeenshowntobeindependentof opioidrecep-
tor signalling (Naleid et al. 2005). Peripheral injection of
naltrexone has been shown to blocks the reinforcing
properties of alcohol in rodents (Herz 1997), suggesting
that naltrexone passes the blood-brain barrier and has
central effects. Even though opioid receptors, speciﬁcally
the m receptor, mediate drug-induced reinforcement this
receptor appear to be less important for the ability of
ghrelin to activate the mesolimbic dopamine system.
Orexin-containing neurons have previously been sug-
gested to regulate ghrelin-induced feeding (Toshinaiet al.
2003), but orexin A receptors do not appear to be crucial
for the locomotor stimulatory effects of ghrelin. Collec-
tively, these data suggest that ghrelin-induced activation
of the mesolimbic dopamine system appears to be regu-
lated via other mechanisms than its orexigenic proper-
ties. In the present study, it was shown that ventral
tegmental NMDA receptors are required for ghrelin-
induced locomotor stimulation and accumbal dopamine
release. Supportively, the effects of ghrelin to increase the
electrical activity of dopaminergic neurons in the VTA
appears to be dependent on the excitatory glutamatergic
input and also blockade of NMDA receptors in the VTA
reduces food-induced accumbal dopamine release (Taber
& Fibiger 1997; Abizaid et al. 2006). NMDA receptors
havealsobeenshowntomediatetheaccumbaldopamine
release observed when animals consume food after
ghrelinadministration(Kawaharaet al.2009).Asshown
previously, ghrelin-induced reinforcement also involves
nicotinicacetylcholinereceptorsintheVTA(Jerlhaget al.
2006;Jerlhaget al.2008).Collectively,thesedatasuggest
that neurotransmitters including acetylcholine and
glutamate are required for ghrelin-induced reinforce-
ment, which it has in common with natural as well as
chemicalreinforcersof themesolimbicdopaminesystem.
The mechanisms for the interaction between ghrelin,
acetylcholine and glutamate in the VTA are still unclear.
However, presynaptic nicotinic acetylcholine receptors
have been shown to modulate the release of glutamate in
the VTA, which via postsynaptic NMDA receptors regu-
late accumbal dopamine release (Schilström et al. 1998;
Schilström et al. 2000).Tentatively, ghrelin may increase
the acetylcholine release, which via such mechanisms
may indirectly activate the mesolimbic dopamine system.
However, the possibility of the existence of presynaptic
NMDA receptors on cholinergic neurons cannot be
excluded(Corlewet al.2008).Thepossibilitythatghrelin
has an ability to rearrange the excitatory NMDA-
mediatedsynapticinputinamannerthatwouldincrease
the probability of activation of the dopamine neurons by
other inputs should also be considered; thus ﬁndings in
the hippocampus as well as VTA show that ghrelin has
effects on synaptic plasticity (Abizaid et al. 2006; Diano
et al. 2006). The glutamatergic afferents to the VTA
mainly originate from the prefrontal cortex, lateral hypo-
thalamus, bed nucleus of stria terminalis, superior coli-
culus and the LDTg. This input regulates the activity of
dopamine via NMDA receptors (Schilström et al. 1998;
Georges & Aston-Jones 2002; Geisler & Zahm 2005). It
should however be emphasized that other afferents
including GABA, serotonin and noradrenalin, known to
modulate the activity of dopamine projections to the
N.Acc. (Wise 2002), may also have important roles for
the ghrelin-induced activation of the mesolimbic dopam-
ine system. Although, GABAA receptors in the VTA does
notmediatetheincreaseinaccumbaldopamineobserved
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et al. 2009).
In summary, the present study shows that the effects
of peripheral ghrelin on locomotor stimulation and
accumbal dopamine release in mice (that reﬂect
direct actions of ghrelin at the level of the mesolimbic
dopaminesystem,speciﬁcallytheVTA)canbesuppressed
by an NMDA antagonist and are therefore likely to be
under glutamatergic control. These data may have clini-
cal implications since hyperghrelinemia is associated
with addictive behaviours including compulsive overeat-
ing and alcohol use disorder (Cummings et al. 2001; Kim
et al. 2005; Kraus et al. 2005). It may therefore be pro-
posed that ghrelin-responsive circuits at the level of the
VTA, that appear to be sensitive to cholinergic and
glutamatergic input, may serve as a novel pharmacologi-
cal target for treatment of such addictive behaviours.
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